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Abstract
Background: Arthritic disorders can be the cause of hospitalizations, especially among individuals 60 years and
older. The objective of this study is to investigate associations between health care resource utilization in arthritis
patients with and without concomitant anemia in a secondary care setting in France.
Methods: This retrospective cohort study utilized data on secondary care activity in 2001 from the Programme de
Médicalisation des Systèmes d’Information database. Two cohorts were defined using ICD-10 codes: patients with
an arthritis diagnosis with a concomitant diagnosis of anemia; and arthritis patients without anemia. Health care
resource utilization for both populations was analyzed separately in public and private hospitals. Study outcomes
were compared between the cohorts using standard bivariate and multivariable methods.
Results: There were 300,865 hospitalizations for patients with arthritis only, and 2,744 for those with concomitant
anemia. Over 70% of patients with concomitant anemia were in public hospitals, compared with 53.5% of arthritis-
only patients. Arthritis patients without anemia were younger than those with concomitant anemia (mean age 66.7
vs 74.6, public hospitals; 67.1 vs 72.2, private hospitals). Patients with concomitant anemia/arthritis only had a mean
length of stay of 11.91 (SD 14.07)/8.04 (SD 9.93) days in public hospitals, and 10.68 (SD 10.16)/9.83 (SD 7.76) days in
private hospitals. After adjusting for confounders, the mean (95% CI) additional length of stay for arthritis patients
with concomitant anemia, compared with those with arthritis only, was 1.56 (1.14-1.98) days in public and 0.69
(0.22-1.16) days in private hospitals. Costs per hospitalization were €;480 (227-734) greater for arthritis patients with
anemia in public hospitals, and €;30 (-113-52) less in private hospitals, than for arthritis-only patients.
Conclusions: Arthritis patients with concomitant anemia have a longer length of stay, undergo more procedures,
and have higher hospitalization costs than nonanemic arthritis patients in public hospitals in France. In private
hospitals, concomitant anemia was associated with modest increases in length of stay and number of procedures;
however, this did not translate into higher costs. Such evidence of anemia-related health care utilization and costs
can be considered as a proxy for the clinical significance of anemia.
Background
Arthritis and other rheumatic conditions are a signifi-
cant public health issue, and are estimated to affect
more than 21% of adults [1]. Osteoarthritis (OA), the
most common form of arthritis, is a major cause of dis-
ability [2,3] and presents a significant burden to health
care providers [4]. In approximately 10% of the world’s
population aged 60 years or more, OA-related joint
pathology causes significant clinical problems [5]. Rheu-
matoid arthritis (RA) is less prevalent but is associated
with high medical expenses because of the requirement
for continuous treatment to slow disease progression,
and a high incidence of joint replacements [6]. Hospita-
lization represents a significant component of the costs
associated with arthritis [7,8].
Anemia, defined by the World Health Organization
[9] as a hemoglobin concentration below 12 g/dl in
women and 13 g/dl in men, is common in people with
arthritis. Anemia is associated with increased morbidity,
length of hospitalization, and cost of care delivery [10].
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any medium, provided the original work is properly cited.In RA, it is estimated that 30-60% of patients are anemic
[11-14]. One of the most frequent causes of anemia in
RA patients is “iron deficiency anemia,” which can result
from gastrointestinal (GI) bleeding related to nonsteroi-
dal anti-inflammatory drug (NSAID) use [15,16]. “Ane-
mia of chronic disease,” which does not usually respond
to iron supplementation, is another major cause of ane-
mia in patients with RA [17,18]. In a study of 225
patients with RA, anemia of chronic disease accounted
for 77% and iron deficiency anemia for 23% of observed
anemia [14]. There are few data on the prevalence of
anemia in patients with OA, although the prevalence of
both conditions is known to increase with age [5,19-21].
Sex also appears to influence disease prevalence; OA
appears to affect more women than men, while current
estimates suggest that women are up to three times
more likely to develop RA than men [22]. Women are
also at a greater risk of becoming anemic than men,
particularly during menstruation or pregnancy, when
iron requirements are increased [23].
Information on the impact of anemia in arthritic
populations is also limited, although there is evidence
that anemic RA patients have more severe arthritic dis-
ease than nonanemic patients [14,24,25]. Studies in
other populations have demonstrated that the clinical
impact of anemia is substantial: for example in chroni-
cally ill patients, anemia has been associated with an
increased risk of mortality and morbidity while also
having a negative impact on quality of life [18]; Anand
and colleagues also demonstrated that anemic patients
with chronic heart failure have greater disease severity
and have a higher risk of hospitalization or death [26].
Adverse outcomes related to anemia may be of parti-
cular importance in the elderly, in whom anemia (and
arthritic disease) is common [19]. Penninx et al. have
associated anemia in elderly populations with an
increased risk of hospitalization (adjusted relative risk
1.27 [95% confidence interval [CI] 1.12-1.45]) and mor-
tality (relative risk 1.61 [95% CI 1.34-1.93]) [27], as
well as disability, poor physical performance, and
decreased muscle strength [28-30]. In community-
dwelling older women, even mild anemia and low-
normal hemoglobin levels have been identified as inde-
pendent risk factors for frailty: compared with a hemo-
globin concentration of 13.5 g/dl, adjusted odds
for frailty of 11.5 g/dl and 12 g/dl were 1.9 (95% CI
1.1-3.4) and 1.5 (95% CI 1.0-2.1) [31].
Anemia has also been linked to increased health care
costs and resource utilization [32], with direct medical
costs for anemic patients with comorbid conditions up
to twice those for nonanemic patients with the same
comorbid condition [33,34]. However, data on anemia-
associated resource use and cost in people with arthritis
remain very sparse.
The objective of this study was to assess differences in
health resource utilization patterns among arthritis (OA
and RA) patients with concomitant anemia compared
with those without anemia. We analyzed data from
French hospital admissions to test the hypothesis that
arthritis patients with concomitant anemia are asso-
ciated with more health care resource use than nonane-
mic arthritis patients.
Methods
Study design
This retrospective cohort study utilized data on second-
a r yc a r ei nF r a n c ef r o mt h eP r o g r a m m ed eM é d i c a l i s a -
tion des Systèmes d’Information (PMSI) database. For
public and private hospitals, two cohorts were identified
from the hospitalizations that occurred during the 2001
calendar year: hospitalizations where there was a pri-
mary/secondary diagnosis of arthritis without anemia;
and hospitalizations where there was both a primary/
secondary diagnosis of arthritis and a primary/secondary
diagnosis of anemia. Thus, both cohorts were comprised
of arthritis patients, but differed in the presence or
absence of anemia diagnosis, respectively. The cohorts
were compared for the following measures of hospital
resource utilization: length of stay, number of proce-
dures, and mean total cost.
The PMSI database covers more than 90% of private
and public hospital activity in France and is used by
government and regional health authorities as a tool to
provide hospital activity indicators for allocating annual
budget and forecasting medical needs and resources.
Even though the PMSI database is not exhaustive of
French hospitals, it guarantees a standardized collection
of data that allows the unbiased identification of cases
and controls for epidemiological studies. For each hos-
pital stay, the PMSI database includes information on
the patient’s age, sex, and postal region; their primary,
secondary, and related diagnoses; procedures underta-
ken; and length of stay. Use of PMSI to assess the
epidemiological and economic burden of illness is
recommended by the French guidelines for health
economic evaluation [35].
Patients admitted to a hospital were classified by pri-
mary diagnosis and then allocated a randomized code to
maintain anonymity. Access to patient information
thereafter was available only at the hospital admission
or hospital stay level. The two study cohorts were iden-
tified from the PMSI database using International Statis-
tical Classification of Diseases and Related Health
Problems, 10th Revision (ICD-10) codes [36]. Arthritis,
defined as RA and/or OA, included seropositive RA
(ICD-10 code M05), other RA (M06), polyarthrosis
(M15), coxarthrosis/hip arthrosis (M16), gonarthrosis/
knee arthrosis (M17), arthrosis of first carpometacarpal
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anemia included iron deficiency anemia (D50.0, D50.1,
D50.8, D50.9), vitamin B12 deficiency anemia (D51.0-
D51.3, D51.8, D51.9), folate deficiency anemia (D52.0,
D52.1, D52.8, D52.9), other nutritional anemias (D53.0-
D53.2, D53.8, D53.9), and acquired hemolytic anemias
(D59.0-D59.6, D59.8, D59.9). Patients with alpha and
beta thalassemia were not included.
Costs
Health care resource utilization for length of stay, num-
ber of procedures, and total cost of stay in public and
private hospitals was analyzed for both study popula-
tions. Costs were assessed from the health care system
perspective, and were calculated according to the French
Diagnosis-Related Group (DRG) system. This system
classifies every hospital patient into one of several hun-
dred DRG groups that are intended to be clinically
meaningful and homogenous with respect to resource
use. The DRG assignment was recorded on the PMSI
dataset for each hospitalization.
Due to differences in the reference costs and financing
systems of public and private hospitals in France, refer-
ence cost information was not equivalent in the two sec-
tors and, therefore, was not directly comparable. For
individual public hospitals in each region, the mean cost
per DRG is calculated and expressed in a synthetic
index, called the ISA (Index Synthétique d’Activité); the
number of ISA points represents an index of hospital
productivity. For public hospitals, the average ISA value
is, in part, calculated by dividing the “short-term stays”
activity budget by the number of ISA points for this
activity. However; for private hospitals or clinics, the
ISA point value is calculated from the expenses reim-
bursed by the public health insurance fund (Social
Security Sick Funds) to these hospitals. Furthermore,
because the financing systems differ, costing for public
and private hospitals has to be performed and inter-
preted separately.
For public hospitals (which represent three quarters of
all hospitalized patients), two published lists of reference
costs were used to calculate costs for hospital stays for
the study populations [37]. The reference costs, calcu-
lated from accountability data from a subgroup of
40 public hospitals, were given per DRG for an average
length of stay for each DRG, allowing calculation of unit
costs per day for each DRG. Total costs of admissions
in each of the two study populations were calculated by
summing the product of the length of stay for each
admission and the appropriate DRG-related unit cost
per day for each admission.
The reference unit costs per hospital stay per DRG
comprised the following: medical and paramedical care
(salaries of clinicians, nurses, and other medical staff);
pharmaceuticals and drugs; anesthesia (including opera-
tion suite); laboratory tests and procedures; intensive
care (medical staff salaries, pharmaceuticals, amortiza-
tion, maintenance, and medical logistics); logistics
(amortization and medical material maintenance, medi-
cal logistics, food service, central laundry, hospital man-
agement); structure (amortization of building and
facilities and committed fixed costs); and reanimation
costs (costs associated with acute care; similar but not
equivalent to intensive care in the US). The average
total cost per stay in public hospitals was broken down
into these categories.
For private hospitals we used the reference cost lists,
calculated on all medical fees reimbursed to patients by
the Social Security Sick Funds [38], to calculate total
costs per stay. Because of the method used for its devel-
opment, the list of reference costs for private hospitals
did not include assessment of detailed items of costs,
such as in the public sector. Only total costs of stay per
DRG, DRG-related procedures, and medical care corre-
sponding to an invoice sent to the Social Security Sick
F u n df o rr e i m b u r s e m e n t ,w e r ea v a i l a b l e .T h u s ,p a r to f
the fixed costs, maintenance, logistics, and salaries are
not included in the private total costs per stay.
Statistical analysis
Our primary analysis was to describe the resource utili-
zation of hospitalized patients with arthritis in the two
study groups (arthritis with anemia cohort and arthritis-
only cohort). The description of resource utilization
data was done by their means and 95% CIs. Five con-
founders of the impact of anemia on resource utilization
were identified: sex (male, female), age (0-59, 60-69, 70-
79, 80+ years), type of primary diagnosis of arthritis
(presence or absence of each of the following diagnoses:
M05, M06, M15, M16, M17, M19), type of secondary/
associated diagnosis of arthritis (presence or absence of
each of the following diagnoses: M05, M06, M15, M16,
M17, M19), and number of associated diagnoses/comor-
bidities (none, 1-2, 3-4, 5-6, 6+).
In order to eliminate the possible effect of these con-
founders on resource utilization when comparing arthri-
tis with anemia and arthritis-only cohorts, we randomly
generated “matched-control” samples from the arthritis
without anemia population based on the five confoun-
ders. Simple random sampling was performed in the
arthritis-only cohort stratified by confounders. The stra-
tum sampling rates were specified as being equal to the
actual percentages observed in the arthritis with anemia
cohort. Five separate replications of this random process
were performed leading to five independent matched-
samples. This approach allowed obtaining five control
samples (no anemia) comparable to the population with
anemia in terms of sociodemographics, diagnostics, and
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described and compared between “matched-control”
samples and the arthritis with anemia population by
their means and 95% CIs.
To further confirm these results, we also conducted
multivariable analyses on the entire study sample,
including the confounding variables and the variable
“anemia yes/no.” We described and compared the
adjusted resource utilization for the two study groups
(arthritis with anemia cohort and arthritis-only cohort)
using analysis of covariance. All data processing and
analyses were performed using SAS software (Statistical
Analysis System, version 8. 2, SAS Institute, Inc., Cary,
NC).
Results
Results for public and private hospitals are presented
separately, because of the inherent differences in care
structure and cost capture in the two settings.
Public hospitals
Number of hospitalizations
In public hospitals in 2001 there were 161,121 hospitali-
zations for the arthritis without anemia population and
1,941 hospitalizations for the arthritis with anemia
population (Table 1). Overall, the prevalence of anemia
with arthritis in public hospitals was 1.2% (1941/
163,062).
Characteristics of study population
The mean age of the arthritis without anemia popula-
tion was slightly lower than that of the arthritis with
anemia population; 66.7 years and 74.6 years, respec-
tively (Table 1). In the arthritis with anemia population,
three quarters of arthritis patients were female, whereas
in the arthritis without anemia population, female
patients comprised approximately two thirds of the
population (Table 1).
Rheumatoid arthritis (nonseropositive RA; 18.5%),
gonarthrosis (11.1%), arthrosis (10.3%), and other pri-
mary coxarthrosis (9.8%) represented the most fre-
quently recorded diagnoses in the arthritis without
anemia population in public hospitals. The most
frequent diagnoses recorded in the hospitalizations of
patients with concomitant arthritis and anemia were
iron deficiency anemia (17.5%), iron deficiency anemia
(secondary to blood loss; 12.7%), and RA (nonseroposi-
tive RA; 11.6%), followed by other iron deficiency ane-
mias (7.4%), polyarthrosis (6.4%), and arthrosis (6%).
On average, patients with arthritis and anemia had a
greater number of associated diagnoses (in addition to
arthritis and/or anemia), compared with arthritis
patients without anemia (5.8 vs 2.5, respectively; Table
1). Essential (primary) hypertension was the most com-
mon associated diagnosis (comorbidity) in the arthritis
with anemia and arthritis without anemia populations,
accounting for 5.9% and 7.5% of associated diagnoses,
respectively. In the arthritis with anemia population, the
most common comorbidities in public hospitals, other
than essential hypertension, were blood transfusion
(2.4%; as defined by ICD-10), atrial fibrillation and flut-
ter (1.4%), diaphragmatic hernia (without obstruction or
gangrene; 1.3%), ulcer of the lower limb (1.1%), and ele-
vated erythrocyte sedimentation rate (1.1%). Other than
essential hypertension, the most frequently reported
comorbidities in the arthritis without anemia population
included obesity (1.5%), type 2 diabetes (without compli-
cation; 1.4%), other chemotherapy or medical care
(1.3%), and atrial fibrillation or flutter (1.2%).
Hospital treatment of study population, descriptive results
Arthritis patients with concomitant anemia stayed sig-
nificantly longer in public hospitals (mean 11.9 [95% CI
11.28-12.54] days) than those without anemia (mean 8.0
[95% CI 7.99-8.09] days) (Table 2). The mean number
of procedures performed on patients in public hospitals
was also significantly greater for those with concomitant
anemia (3.7 [95% CI 3.48-3.92] procedures) than for
patients without anemia (2.6 [95% CI 2.58-2.62] proce-
dures; Table 2).
The types of procedures performed were mainly
related to general anesthesia management/use of recov-
ery room services, cardiovascular function monitoring
(e.g., electrocardiography), and thoracic or abdominal
investigations. In arthritic patients without anemia, pro-
cedures generally focused on the arthritis diagnosis, with
Table 1 Number of hospitalizations and characteristics of study populations
Public Private
Arthritis without anemia Arthritis with anemia Arthritis without anemia Arthritis with anemia
Number of hospitalizations, n (%) 161,121 (98.8) 1,941 (1.2) 139,783 (99.4) 803 (0.6)
Mean age, y (SD) 66.7 (15.1) 74.6 (13.8) 67.1 (12.4) 72.2 (12.4)
Sex, n (%)
Female 108,514 (67.4) 1,484 (76.5) 84,808 (60.7) 601 (74.8)
Male 52,605 (32.7) 457 (23.5) 54,970 (39.3) 202 (25.2)
Number of associated diagnoses Mean (SD) 2.5 (2.5) 5.8 (5.8) 2.2 (2.4) 5.3 (3.3)
Median 2.0 5.0 2.0 5.0
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cements, comprising 7.2% of all procedures in public
hospitals. In patients with concomitant anemia, proce-
dures were more focused on identifying the cause of
anemia and its monitoring, with hip and knee replace-
ments each representing <1% of procedures performed
in public hospitals.
Overall, the mean cost per hospitalization in public
hospitals for the arthritis and anemia population was
€;5,870 (95% CI 5,447-6,293) and €;4,190 (95% CI 4,161-
4,219) for the arthritis without anemia population
(Table 2). In the public hospital sector, anesthesia
accounted for a greater proportion of the total cost of
stay for arthritic patients without concomitant anemia
than those with anemia (13.3 vs 6.0%, Figure 1). How-
ever, the concomitant anemia population had a higher
proportion of cost attributable to laboratory tests and
procedures (11.2 vs 8.9%) and reanimation care (9.1 vs
5.2%).
Hospital treatment of study population, comparative results
Tables 3, 4 and 5 show the results of the univariable
analysis conducted on the “matched-control” samples,
and the multivariable analysis conducted on the whole
population for length of stay, number of procedures,
and total cost, adjusting for sex, age, type of primary
arthritis diagnosis, type of secondary arthritis diagnoses,
and number of associated diagnoses. The results of the
univariable analysis conducted on the matched-control
samples are consistent with the results of the multivari-
able analysis for each outcome.
After adjustment using multivariable analysis on the
whole population, in public hospitals the mean length of
stay for arthritis patients with concomitant anemia,
compared with those with arthritis only, was signifi-
cantly higher, with an additional 1.56 days (95% CI 1.14-
1.98; Table 3) of stay. Arthritic patients with anemia
also underwent significantly more procedures than those
without anemia (0.52 additional procedures; 95% CI
0.38-0.65; Table 4). The additional length of stay and
number of procedures attributable to anemia in public
hospitals represents 20% of the mean length of stay and
number of procedures for nonanemic arthritis patients.
Furthermore, the total cost per hospitalization for arthri-
tis patients with anemia was €;480 greater (95% CI 227-
734) than for patients with arthritis without anemia
(Table 5). The adjusted difference in costs per
Table 2 Resource utilization, descriptive results
a
Public Private
Arthritis without
anemia
Arthritis with
anemia
Arthritis without
anemia
Arthritis with
anemia
n = 161,121 n = 1,941 n = 139,783 n = 803
Mean length of stay, days (SD) 8.0 (9.9) 11.9 (14.1) 9.8 (7.8) 10.7 (10.2)
Missing, n 4,403 26 2,087 25
Mean number of associated procedures
(SD)
2.6 (3.2) 3.7 (4.9) 4.3 (2.8) 4.8 (3.7)
Mean total cost, € (SD) 4,190 (5,940) 5,870 (9,433) 3,380 (2,038) 2,700 (2,100)
Missing, n 4,499 29 188 3
aDue to differences in the reference costs and financing systems of public and private hospitals in France, reference cost information was not equivalent in the
two sectors and, therefore, was not directly comparable.
Figure 1 Cost breakdown in public hospitals
aamong arthritis patients (a) with anemia or (b) without anemia.
aNot available for private
hospitals. ICU, intensive care unit.
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CI 227-734]), represents 11% of the mean cost expendi-
ture for nonanemic arthritis patients.
Private hospitals
Number of hospitalizations
Overall, in 2001 there were 139,783 private hospitaliza-
tions for the arthritis without anemia population and
803 hospitalizations for the arthritis with anemia popu-
lation. Overall, the prevalence of anemia with arthritis
in private hospitals was 0.6% (n = 803/140,586).
Characteristics of study population
As for public hospitalizations, the mean age of the
arthritis with anemia population was slightly greater
than that of the arthritis without anemia population,
72.2 years and 67.1 years, respectively (Table 1). Again,
female patients comprised approximately three quarters
of the arthritis with anemia population and 61% of the
arthritis without anemia population (Table 1).
In terms of the primary or secondary diagnoses in the
arthritis without anemia population, coxarthrosis (other
primary; 20.4%), gonarthrosis (other primary; 17.4%),
gonarthrosis (7.5%), and arthrosis (7.2%) were the most
frequently reported. In patients with arthritis and ane-
mia, the most common diagnoses were iron deficiency
anemia (secondary to blood loss; 18.6%), iron deficiency
anemia (17.6%), RA (nonseropositive RA; 9.1%), and
coxarthrosis (other primary; 7.8%).
Private hospital patients with arthritis and concomi-
tant anemia also had, on average, a greater number of
associated diagnoses (in addition to arthritis and/or ane-
mia), than arthritis patients without anemia (5.3 vs 2.2,
respectively; Table 1). Again, similar for public hospitali-
zations, the most common associated diagnosis was
essential (primary) hypertension, accounting for 8.8%
and 13.3% of associated diagnoses in the arthritis with
anemia and arthritis without anemia populations,
respectively. In arthritic patients with anemia, the most
common associated diagnoses other than essential
hypertension were diaphragmatic hernia (without
obstruction or gangrene; 2.8%), diverticular distension of
the large intestine (without perforation or abscess;
2.1%), blood transfusion (without reported diagnosis;
2.1%), and pure hypercholesterolemia (2.0%). In arthritic
patients without anemia, other than hypertension, the
most common associated diagnoses were pure
Table 3 Differences between arthritis and anemia versus arthritis without anemia in length of stay, adjusted for age,
sex, type of primary diagnosis of arthritis, type of secondary/associated diagnosis of arthritis, and number of
associated diagnoses
Public Private
Difference, days (95% CI) Difference, days (95% CI)
Univariable analysis Matched sample #1 0.91 (0.01 to 1.81) 0.35 (-0.67 to 1.37)
Matched sample #2 0.68 (-0.20 to 1.56) 0.47 (-0.55 to 1.49)
Matched sample #3 1.30 (0.47 to 2.13) 0.79 (-0.19 to 1.77)
Matched sample #4 1.00 (0.11 to 1.89) 0.29 (-0.70 to 1.28)
Matched sample #5 1.13 (0.28 to 1.98) 0.03 (-1.07 to 1.13)
Multivariable analysis Whole population 1.56 (1.14 to 1.98) 0.69 (0.22 to 1.16)
Legend: Matched samples of arthritis patients with anemia and without anemia were identified based on five confounders: Sample #1 - gender (male, female);
Sample #2 - age (0–59, 60–69, 70–79, 80+); Sample #3 - type of primary diagnosis of arthritis; Sample #4 - type of secondary/associated diagnosis of arthritis;
Sample #5 - number of associated diagnoses/comorbidities (none, 1–2, 3–4, 5–6, 6+).
Table 4 Differences between arthritis and anemia versus arthritis without anemia in number of procedures, adjusted
for age, sex, type of primary diagnosis of arthritis, type of secondary/associated diagnosis of arthritis, and number of
associated diagnoses
Public Private
Difference, no of procedures (95% CI) Difference, no of procedures (95% CI)
Univariable analysis Matched sample #1 0.58 (0.29 to 0.87) 0.17 (-0.16 to 0.50)
Matched sample #2 0.48 (0.20 to 0.76) -0.12 (-0.46 to 0.22)
Matched sample #3 0.45 (0.17 to 0.73) 0.14 (-0.20 to 0.48)
Matched sample #4 0.44 (0.16 to 0.72) 0.02 (-0.32 to 0.36)
Matched sample #5 0.45 (0.18 to 0.72) 0.17 (-0.17 to 0.51)
Multivariable analysis Whole population 0.52 (0.38 to 0.65) 0.08 (-0.11 to 0.27)
Legend: Matched samples of arthritis patients with anemia and without anemia were identified based on five confounders: Sample #1 - gender (male, female);
Sample #2 - age (0–59, 60–69, 70–79, 80+); Sample #3 - type of primary diagnosis of arthritis; Sample #4 - type of secondary/associated diagnosis of arthritis;
Sample #5 - number of associated diagnoses/comorbidities (none, 1–2, 3–4, 5–6, 6+).
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betes (without complication; 2.1%), and varicose veins of
the lower extremities (without ulcer or inflammation;
1.5%).
Hospital treatment of study population, descriptive results
In private hospitals, the mean unadjusted length of stay
for arthritis patients with anemia was 10.7 (95% CI 9.97-
11.39) days, versus 9.8 (95% CI 9.79-9.87) days for
arthritis patients without anemia (Table 2). In private
hospitals, patients underwent more procedures than in
public hospitals (mean 4.8 [95% CI 4.57-5.07] for ane-
mic arthritis patients and 4.3 [95% CI 4.28-4.30] for
nonanemic patients; Table 2).
As for public hospitals, the types of procedures per-
formed were mainly related to general anesthesia man-
agement/use of recovery room services, cardiovascular
function monitoring (e.g., electrocardiography), and
thoracic or abdominal investigations. In arthritic
patients without anemia, procedures generally focused
on the arthritis diagnosis, with major surgeries underta-
ken, such as hip and knee replacements, comprising
12% of all procedures in private hospitals. In patients
with concomitant anemia, procedures were more
focused on identifying the cause of anemia and its mon-
itoring, with hip and knee replacements (combined)
representing 7% (hip and knee combined) of all proce-
dures in private hospitals.
In private hospitals, the mean cost per hospitalization
for the arthritis and anemia population was €;2,700
(95% CI 2,554-2,846) compared with €;3,380 (95% CI
3,369-3,391) for the arthritis without anemia population
(Table 2).
Hospital treatment of study population, comparative results
Tables 3, 4 and 5 show the results of the univariable and
multivariable analysis conducted on the matched-control
and whole population samples for length of stay, num-
ber of procedures, and total cost, adjusting for sex, age,
type of primary arthritis diagnosis, type and number of
secondary arthritis diagnoses, and number of associated
diagnoses. The results of the univariable analysis con-
ducted on the matched-control samples are consistent
with the results of the multivariable analysis for each
outcome.
In private hospitals, after adjustment using multivari-
able analysis on the whole population, the differences
between the anemic and nonanemic populations in
length of stay and number of procedures were more
modest than those seen in public hospitals (0.69 days
[95% CI 0.22-1.16] and 0.08 procedures [95% CI -0.11
to 0.27], respectively; Tables 3 and 4). The total cost
per private hospitalization was €;30 less (95% CI -113 to
52) for arthritis patients with anemia than for patients
with arthritis who did not have concomitant anemia
(Table 5).
In both public and private hospitals, the combined
total economic burden of all hospitalizations for arthritis
patients with and without anemia was €;13.6 million and
€;1.15 billion, respectively. Of the €;13.6 million,
€;907,590 was attributable to anemia.
Discussion
This retrospective cross-sectional study assessed the
2001 hospital health care utilization and costs related to
anemia in arthritis patients in France. The study showed
that, in public hospitals, arthritis patients with concomi-
tant anemia use more health care resources than those
without anemia. After adjustment for confounders, the
length of stay and number of procedures attributable to
anemia were greater in public than in private hospitals.
Although it was not possible to directly compare the
two populations due to the way in which these costs
were calculated, the cost of stay per hospitalization in
public hospitals was greater in patients with concomi-
tant anemia than in those without anemia, while in pri-
vate hospitals anemia was associated with a modest
decrease in the total cost of stay.
Table 5 Differences between arthritis and anemia versus arthritis without anemia in total cost, adjusted for age, sex,
type of primary diagnosis of arthritis, type of secondary/associated diagnosis of arthritis, and number of associated
diagnoses
Public Private
Difference, € (95% CI) Difference, €; (95% CI)
Univariable analysis Matched sample #1 280 (-320 to 880) 26 (-180 to 232)
Matched sample #2 144 (-416 to 704) 28 (-178 to 234)
Matched sample #3 371 (-193 to 935) -11 (-219 to 197)
Matched sample #4 167 (-451 to 785) -21 (-228 to 186)
Matched sample #5 374 (-174 to 922) -58 (-263 to 147)
Multivariable analysis Whole population 480 (227 to 734) -30 (-113 to 52)
Legend: Matched samples of arthritis patients with anemia and without anemia were identified based on five confounders: Sample #1 - gender (male, female);
Sample #2 - age (0–59, 60–69, 70–79, 80+); Sample #3 - type of primary diagnosis of arthritis; Sample #4 - type of secondary/associated diagnosis of arthritis;
Sample #5 - number of associated diagnoses/comorbidities (none, 1–2, 3–4, 5–6, 6+).
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ing specifically at the impact of anemia on health care
resource use in hospitalized populations in Europe.
However, studies assessing overall annual health care
utilization have shown that anemia is associated with
increased resource use and costs [32-34]. In a US study
based on administrative claims data for anemic adults
with RA or one of five other comorbid conditions, utili-
zation of key medical services was significantly higher
(P < 0.001) for anemic than nonanemic patients [34]. In
addition, anemic patients had higher care (including
inpatient) costs than nonanemic patients with the same
comorbid condition, and inpatient and outpatient costs
more than double those for nonanemic patients after
adjustment for confounders. Another US study identi-
fied a difference in direct costs between anemic and
nonanemic RA patients of more than $7,000 per year,
and showed that anemia also impacts indirect health
care costs [33]. Penninx et al. [27] examined the rela-
tionship of anemia with death and hospitalization out-
comes in a community-based sample of older people.
They identified a significant association between anemia
and subsequent mortality and hospitalization (relative
risk 1.61 [95% CI 1.34-1.93] and relative risk 1.27 [95%
CI 1.12-1.45], respectively) and, consistent with the
results from the French public hospital sector in the
current study, found that people with anemia who were
hospitalized had a significantly longer length of stay
than nonanemic patients (25.0 vs 13.7, respectively,
P < 0.001) [27].
The use of a national database representative of hospi-
talizations across France, in conjunction with the large
size of the two study populations involved (303,648
hospitalizations, representing 1.6% of all admissions to
French hospitals in 2001) adds weight to the findings
regarding the impact of anemia in an arthritic popula-
tion. In addition, the adjustment for key factors that
could influence health care resource use, particularly the
primary/secondary diagnosis and number of associated
diagnoses, helps guard against the possibility that ane-
mia is simply a marker for greater morbidity and sever-
ity of underlying disease. Indeed, analysis of the number
and types of procedures performed in anemic and nona-
nemic patients suggests that, in this study, the anemic
population has less severe arthritic disease than the non-
anemic population.
However, this study also has several limitations. First,
as the analyzed data is derived from retrospective analy-
sis of medical claims, the findings do not denote causal-
ity, but rather focus on identifying temporal association
among patient outcomes. We are thus identifying asso-
ciation, not causality, between anemia and increased
resource utilization. Second, care must be taken when
using DRGs as these are sometimes re-coded for billing
purposes and may, therefore, no longer accurately reflect
the actual final diagnosis [39]. Indeed, even though
DRGs are intended to be clinically consistent with
respect to resource use, the calculated costs remain an
average estimate that does not reflect the heterogeneity
among severity of diseases included in the DRG. Third,
t h ep r e v a l e n c eo fa n e m i ai nt h eh o s p i t a l i z e da r t h r i t i s
patients (0.9%) seems low compared with previous esti-
mates of 30-60% prevalence of anemia in people with
RA [11-14], which may have biased the outcome. How-
ever, most patients in this analysis were OA patients, in
w h o mt h ep r e v a l e n c eo fa n e m i am a yn o tb ea sh i g h .
Moreover, our study did not include patients with “ane-
mia of chronic disease,” a common type of anemia in
people with RA [18,17]. Another possible reason for the
low percentage of anemic patients in this study is that
anemia is often presented and treated in the primary
care setting, and thus may have been successfully treated
in a proportion of the study population before they were
hospitalized. A fourth limitation is that the database
identifies “admission” and not “patient,” so some
patients may have been counted twice (if they had two
admissions for their arthritis or anemia during the year).
Additionally, the database identifies only admissions for
which the anemia or arthritis required a specific treat-
ment of the patient during his or her admission.
Arthritic/anemic patients who were admitted to the hos-
pital for a reason other than their arthritis/anemia were
not identified. Last, anemia was measured as the hemo-
globin threshold and did not take into account its sever-
ity and clinical impact.
It is interesting that the results of this study show an
anemia-attributable increase in resource utilization and
cost in public but not in private hospitals. A small
increase was observed in the length of stay of anemic
versus nonanemic patients in the private sector, but this
did not translate into increased costs, probably because
of the less detailed way in which costs are reported for
this sector. In private hospitals, because only total costs
of stay per DRG (comprising procedures 0 and medical
care corresponding to an invoice sent to the Social
Security Sick Fund for reimbursement) were available,
part of the fixed costs such as, maintenance, logistics,
and salaries, were not included in the private total costs
per stay 0.
In private hospitals, the anemia-related increase in
length of stay was less than half that observed for public
hospitals, and there was no difference in the number of
procedures undergone by anemic and nonanemic
patients. It is possible that the presence of anemia has a
greater impact in patients who are generally more
unwell than in those who are not as sick. In this study,
diagnoses of patients in private hospitals were generally
less severe (for example, there were fewer RA patients
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nificantly lower) than those in public hospitals, reflecting
the different characteristics of the two sectors: public
hospitals, which are mostly teaching hospitals, offer
more technical and innovative procedures and allow
treatment of more severe cases than private centers,
which are more sensitive to activity profitability.
Furthermore, differences in financial incentives, corre-
sponding to an increased stay in either public or private
hospitals, may have also influenced these findings,
though this is beyond the current scope of the paper
and further studies are warranted.
These study findings are important given that iron
deficiency, which is an important cause of anemia in
arthritis patients, is partially preventable. Although not
proven, the upper GI complications associated with
nonselective NSAID use, including ulceration, perfora-
tion, and bleeding, could contribute to iron deficiency
anemia in arthritis patients using these drugs [15,16,40].
Lower GI events are also an important contributor to
safety throughout the entire GI tract [41-43] and may
contribute to anemia, although there is no literature in
anemic patients per se. Our data showing that anemia
increases health care utilization in patients with arthritis
suggest that treatment options should be examined care-
fully with consideration of the complete patient profile.
Conclusion
In conclusion, the study hypothesis was confirmed in
French public hospital settings; a clear difference in
health care resource use attributable to anemia, adjust-
ing for five confounders, exists in public hospitalizations.
In private hospital settings, the additional resource use
due to anemia was not clearly shown. This was probably
due to the fact that patients seen in private hospitals
have a less severe condition than those in public set-
tings. These French database analyses provide some of
the first evidence of the health care utilization and costs
related to anemia specifically in patients with arthritis,
and can be considered as a measure for the clinical sig-
nificance of anemia. Overall, these findings warrant clo-
ser consideration of anemic arthritis patients in the
clinical setting, and further research to better clarify the
impact of anemia in populations with arthritis. Analysis
of hospital databases in other European and non-Eur-
opean countries would enhance the available evidence
regarding the impact of anemia in patients with OA
and/or RA.
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